Effects of the tumour necrosis factor-α inhibitors pentoxifylline and thalidomide in short-term experimental oral mucositis in hamsters

European Journal of Oral Sciences

Volumn 113, Issue 3, 2005, Pages 210-217

  Lima, V ^a,b   Brito, G A C ^a   Cunha, F Q ^c   Reboucas C G ^a   Falcao B A A ^a   Augusto, R F ^a   Souza, M L P ^a   Leitao B T ^a   Ribeiro, R A ^a  

^a FEDERAL UNIVERSITY OF CEARÁ   (Brazil)

^b UNIVERSITY OF FORTALEZA   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

5 fluorouracil; Animal model; Oral mucositis; Pentoxifylline; Thalidomide

Indexed keywords

FLUOROURACIL; MYELOPEROXIDASE; PENTOXIFYLLINE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLOOD; CANCER THERAPY; CELL INFILTRATION; CHEEK POUCH; CONTROLLED STUDY; CYTOKINE PRODUCTION; EDEMA; ENZYME ACTIVITY; ENZYME ASSAY; ERYTHEMA; HAMSTER; HISTOLOGY; HYPEREMIA; INFLAMMATORY CELL; LEUKOCYTE DIFFERENTIAL COUNT; MALE; MICROSCOPY; MUCOSA INFLAMMATION; NEUTROPHIL; NEUTROPHILIA; NONHUMAN; PATHOPHYSIOLOGY; STOMATITIS; ULCER; WEIGHT REDUCTION;

ABSCESS; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; CRICETINAE; DISEASE MODELS, ANIMAL; EDEMA; ERYTHEMA; FLUOROURACIL; HEMORRHAGE; HYPEREMIA; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; MALE; MESOCRICETUS; MOUTH MUCOSA; NEUTROPHILS; ORAL ULCER; PENTOXIFYLLINE; PEROXIDASE; PROTECTIVE AGENTS; STOMATITIS; THALIDOMIDE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 21144435440     PISSN: 09098836     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0722.2005.00216.x     Document Type: Article

References (41)

1. SONIS ST, LINDQUIST L, VAN VUGT A, STEWART A, STAM K, QU G-Y, IWATA KK, HALEY JD. Prevention of chemotherapy-induced ulcerative mucositis by transforming growth factor β3. Cancer Res 1994; 54: 1135-1138.
2. PETERSON DE. Oral toxicity of chemotherapeutic agents. Semin Oncol 1992; 19: 478-491.
3. SONIS ST, FEY EG. Oral complications of cancer therapy. Oncology 2002; 16: 680-686.
4. SONIS S, CLARK J. Prevention and management of oral mucositis induced by antineoplastic therapy. Oncology 1991; 5: 6-10.
5. SONIS ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4: 277-284.
6. SONIS ST, ELTING LS, KEEFE D, PETERSON D, SCHUBERT M, HAUER-JENSEN M, BEKELE BN, RABER-DURLACHER J, DONNELLY JP, RUBESTEIN EB. Perspectives on cancer therapy-induced mucosal injury. Cancer 2004; 100: 1995-2025.
7. PARIS F, FUKS Z, KANG A, CAPODIECI P, JUAN G, EHLEITER D, HAIMOVITZ-FRIEDMAN A, CORDON-CARDO C, KOLESNICK R. Endothelial apoptosis as the primary lesion initiating radiation damage in mice. Science 2001; 293: 293-297.
8. SONIS ST. Mucositis as a biological process: a new hypothesis for the development of chemotherapy-induced stomatotoxicity. Oral Oncol 1998; 34: 39-43.
9. MCCARTHY GM, AWDE JD, GHANDI H, VINCENT M, KOCHA WI. Risk factors associated with mucositis in cancer patients receiving 5-fluorouracil. Oral Oncol 1998; 34: 484-490.
10. HERRSTEDT J. Prevention and management of mucositis in patients with cancer. Int J Antimicrob Agents 2000; 16: 161-163.
11. NEUNER P, KLOSNER G, SCHAUER E, POURMOJIB M, MACHEINER W, GRUNWALD C, KNOBLER R, SCHWARZ A, LUGER TA, SCHWARZ T. Pentoxifylline in vivo down-regulates the release of IL-1 beta, IL-6, IL-8 and tumour necrosis factor-alpha by human peripheral blood mononuclear cells. Immunology 1994; 83: 262-267.
12. DOHERTY GM, JENSEN JC, ALEXANDER HR, BURESH CM, NORTON JA. Pentoxifylline suppression of tumor necrosis factor gene transcription. Surgery 1991; 110: 192-198.
13. HAN J, THOMPSON P, BEUTLER B. Dexamethasone and pentoxifylline inhibit endotoxin-induced cachetin/tumor necrosis factor synthesis at separate points in the signaling pathway. J Exp Med 1990; 172: 391-394.
14. TILG H, EIBL B, PICHL M, GACHTER A, HEROLD M, BRANKOVA J, HUBER C, NIEDERWIESER D. Immune response modulation by pentoxifylline in vitro. Transplantation 1993; 56: 196-201.
15. MARRIOTT JB, MULLER G, STIRLING D, DALGLEISH AG. Immunotherapeutic and antitumour potential of thalidomide analogues. Expert Opin Biol Ther 2001; 1: 675-682.
16. JACOBSON JM, GREENSPAN JS, SPRITZLER J, KETTER N, FAHEY JL, JACKSON JB, FOX L, CHERNOFF M, WU AW, MACPHAIL LA, VASQUEZ GJ, WOHL DA. Thalidomide for the treatment of oral aphthous ulcers in patients with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med 1997; 336: 1487-1493.
17. NATIONAL RESEARCH COUNCIL. Guide for the Care and Use of Laboratory Animals. Institute of Laboratory Animal Resources, Commission on Life Sciences, National Research Council. National Academy Press, Washington, DC 1996.
18. MOREIRA AL, WANG J, SARNO EN, KAPLAN G. Thalidomide protects mice against LPS-induced shock. Braz J Med Biol Res 1997; 30: 1199-1207.
19. SONIS ST, TRACEY C, SHKLAR G, JENSON J, FLORINE D. An animal model for mucositis induced by cancer chemotherapy. Oral Surg Oral Med Oral Pathol 1990; 69: 437-443.
20. LIMA V, BEZERRA MM, ALENCAR VBM, VIDAL FDP, ROCHA FAC, BRITO GAC, RIBEIRO RA. Effects of chlorpromazine on alveolar bone loss in experimental periodontal disease in rats. Eur J Oral Sci 2000; 108: 123-129.
21. BRADLEY PP, CHRISTENSEN RD, ROTHSTEIN G. Cellular and extracellular myeloperoxidase in pyogenic inflammation. Blood 1982; 60: 618-622.
22. SONIS ST, VAN VUGT AG, BRIEN JPO, MUSKA AD, BRUSKIN AN, ROSE A, HALEY JD. Transforming growth factor-β3 mediated modulation of cell cycling and attenuation of 5-fluorouracil induced oral mucositis. Oral Oncol 1997; 33: 47-54.
23. GIFFORD GE, LOHMANN-MATTHES ML. Gamma interferon priming of mouse and human macrophages for induction of tumor necrosis factor by bacterial lipopolysaccharides. J Natl Cancer Inst 1987; 78: 121-124.
24. SCHADE UF. Pentoxifylline increases survival in murine endotoxin shock and decreases formation of tumor necrosis factor. Circ Shock 1990; 31: 171-181.
25. NOEL P, NELSON S, BOKULIC R, BAGBY G, LIPPTON H, LIPSCOMB G, SUMMER W. Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality. Life Sci 1990; 47: 1023-1029.
26. D'HELLENCOURT CL, DIAW L, CORNILLET P, GUENOUNOU M. Differential regulation of TNF alpha, IL-1 beta, IL-6, IL-8, TNF beta, and IL-10 by pentoxifylline. Int J Immunopharmacol 1996; 18: 739-748.
27. TSENG S, PAK G, WASHENIK K, POMERANZ MK, SHUPACK JL. Rediscovering thalidomide: a review of its mechanism of action, side effects, and potential uses. J Am Acad Dermatol 1996; 35: 969-979.
28. SAMPAIO EP, SARNO EN, GALILLY R, COHN ZA, KAPLAN G. Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes. J Exp Med 1991; 173: 699-703.
29. MOREIRA AL, SAMPAIO EP, ZMUIDZINAS A, FRINDT P, SMITH KA, KAPLAN G. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. J Exp Med 1993; 177: 1675-1680.
30. SAMPAIO EP, KAPLAN G, MIRANDA A, NERY JAC, MIGUEL CP, VIANA SM, SARNO EN. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum. J Infect Dis 1993; 168: 408-414.
31. TRAMONTANA JM, UTAIPAT U, MOLLOY A, AKARASEWI P, BURROUGHS M, MAKONKAWKEYOON S, JOHNSON B, KLAUSNER JD, ROM W, KAPLAN G. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1: 384-397.
32. KLAUSNER JD, MAKONKAWKEYOON S, AKARASEWI P, NAKATA K, KASINRERK W, CORRAL L, DEWAR RL. The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11: 247-257.
33. SONIS S, EDWARDS L, LUCEY C. The biological basis for the attenuation of mucositis: the example of interleukin-11. Leukemia 1999; 13: 831-834.
34. KRENGER W, FERRARA JL. Graft-vs-host disease and the Th1/Th2 paradigm. Immunol Res 1996; 15: 50-73.
35. BIANCO JA, APPELBAUM FR, NEMUNAITIS J, AMGREN J, ANDREWS F, KETTNER P, SHIELDS A, SINGER JW. Phase I-II trial of pentoxifylline for the prevention of transplant-related toxicities following bone marrow transplantation. Blood 1991; 78: 1205-1211.
36. VERDI CJ, GAREWAL HS, KOENIG LM, VAUGHN B, BURKHEAD T. A double-blind, randomized, placebo-controlled, crossover trial of pentoxifylline for the prevention of chemotherapy-induced oral mucositis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1995; 80: 36-42.
37. CLARKE E, RICE GC, WEEKS RS, JENKINS N, NELSON R, BIANCO JA, SINGER JW. Lisofylline inhibits transforming growth factor beta release and enhances trilineage hematopoietic recovery after 5-fluorouracil treatment in mice. Cancer Res 1996; 56: 105-112.
38. HAMMERSCHMIDT DE, KOTASEK D, MCCARTHY T, HUH P-W, FREYBURGER G, VERCELLOTTI GM. Pentoxifylline inhibits granulocyte and platelet function, including granulocyte priming by platelet activating factor. J Lab Clin Med 1988; 112: 254-263.
39. TOOMEY D, REDMOND HP, BOUCHIER-HAYES D. Mechanisms mediating cancer cachexia. Cancer 1995; 76: 2418-2426.
40. ERIKSSON T, BJÖRMAN S, HÖGLUND P. Clinical pharmacology of thalidomide. Eur J Clin Pharmacol 2001; 57: 365-376.
41. LIMA V, VIDAL FDP, ROCHA FAC, BRITO GAC, RIBEIRO RA. Effects of TNF-α inhibitors pentoxifylline and thalidomide on alveolar bone loss in short-term experimental periodontal disease in rats. J Periodontol 2004; 75: 156-162.